After reporting an 80% revenue jump and EBITDA positivity in Q2FY26, Medikabazaar plans 40% annual growth over the next three years, even as it navigates a high-profile boardroom disputeAfter reporting an 80% revenue jump and EBITDA positivity in Q2FY26, Medikabazaar plans 40% annual growth over the next three years, even as it navigates a high-profile boardroom dispute Latest News [ SOBAN NEWS: International and National ]
